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Calcineurin-nuclear factor of activated T cells signaling controls the differentiation and function
of osteoclasts and osteoblasts, and regulator of calcineurin-2 (Rcan2) is a physiological inhibitor of
this pathway. Rcan2 expression is regulated by T3, which also has a central role in skeletal devel-
opment and bone turnover. To investigate the role of Rcan2 in bone development and mainte-
nance, we characterized Rcan2/mice and determined its skeletal expression in T3 receptor (TR)
knockout and thyroid-manipulated mice. Rcan2/mice had normal linear growth but displayed
delayed intramembranous ossification, impaired cortical bone formation, and reduced bonemin-
eral accrual during development as well as increased mineralization of adult bone. These abnor-
malities resulted from an isolated defect in osteoblast function and are similar to skeletal pheno-
types ofmice lacking the type 2 deiodinase thyroid hormone activating enzymeorwith dominant-
negative mutations of TR, the predominant TR isoform in bone. Rcan2 mRNA was expressed in
primary osteoclasts and osteoblasts, and its expression in bone was differentially regulated in TR
and TR knockout and thyroid-manipulated mice. However, in primary osteoblast cultures, T3
treatment did not affectRcan2mRNAexpressionor nuclear factor of activated T cells c1 expression
andphosphorylation. Overall, these studies establish that Rcan2 regulates osteoblast function and
its expression in bone is regulated by thyroid status in vivo. (Endocrinology 153: 3537–3548, 2012)
Regulator of calcineurin (RCAN)-2 belongs to a familyof conserved proteins (RCAN1, RCAN2, and
RCAN3) that inhibit calcineurin (1, 2). Calcineurin is a
Ca2- and calmodulin-activated serine-threonine protein
phosphatase that consists of a calmodulin-binding cata-
lytic subunit andCa2-binding regulatory subunit (3).Ac-
tivation of calcineurin results in dephosphorylation of nu-
clear factor of activated T cells (NFAT), enabling it to
enter the nucleus and regulate gene expression in associ-
ation with other transcription factors, including activator
protein 1 (1, 2, 4, 5). Interaction of RCAN2 with the cat-
alytic subunit of calcineurin blocks NFAT-regulated gene
expression (6, 7), indicating RCAN2 is a physiological
inhibitor of calcineurin-NFAT signaling.
Calcineurin and NFAT are essential for osteoclast dif-
ferentiation and bone resorption. NFAT is a master tran-
scription factor for osteoclast differentiation, functioning
as a point of convergence for the receptor activator of
nuclear factor-B ligand, TNF receptor-associated factor
6 and c-Fos signaling pathways required for osteoclasto-
genesis (8). In addition to its important role in osteoclasts,
NFATalso regulates bonemass by acting in osteoblasts, in
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which its functions are more controversial. Initial studies
inmicewith global disruptionor activationof calcineurin-
NFAT signaling suggested the pathway stimulates osteo-
blast differentiation and bone formation in vivo and in
vitro (9–11), whereas recent studies specifically targeting
osteoblasts suggest the calcineurin-NFAT pathway is a
negative regulator of osteoblast differentiation and bone
formation that also inhibits osteoclastogenesis indirectly
via its effects on osteoprotegerin and receptor activator of
nuclear factor-B ligand in osteoblasts (12). The negative
effects on bone formation are supported by findings that
low doses of the calcineurin antagonist cyclosporin A in-
crease osteoblast differentiation and bonemass (13).Nev-
ertheless, cyclosporinAhas biphasic effects on osteoblasts
(12), and treatment of organ transplant patients with cal-
cineurin inhibitors is associated with high bone turnover
osteoporosis (14). Taken together, these data indicate the
regulatory effects of the calcineurin-NFAT pathway on
bone turnover are complex and involve direct actions in
osteoblasts and osteoclasts as well as indirect osteoblast-
mediated effects on osteoclastogenesis.
The human homolog of RCAN2 (previously named
ZAKI-4) was originally identified as a thyroid hormone
(T3)-responsive gene in skin fibroblasts by differential dis-
play (15), and ZAKI-4 and - mRNA isoforms were
identified subsequently (16). RCAN2–3 expression (pre-
viouslynamedZAKI-4) is restricted tobrainandencodes
a 197-amino acid short protein isoform RCAN2-S. By
contrast, RCAN2–1 (previously named ZAKI-4) is dis-
tributed widely, with the highest levels of expression in
brain, heart, skeletal muscle, and kidney, and encodes a
243-amino acid long protein isoform RCAN2-L (2, 16)
(Fig. 1). Although the two isoforms display tissue-specific
differences in expression, it is unknown whether they are
functionally distinct. Nevertheless, only RCAN2–3
(ZAKI-4) mRNA was found to be T3 responsive in fi-
broblasts (16), and this response was mediated by a non-
genomic signaling cascade involving T3 receptor (TR)-,
phosphatidylinositol 3-kinase-Akt/protein kinase B, and
mammalian target of rapamycin (17). T3 treatment also
resulted in reduced endogenous calcineurin activity, and
RCAN2 proteins were shown to interact directly with cal-
cineurin and inhibit calcineurin-NFAT signaling, indicat-
ingRCAN2 is aT3-responsive endogenous inhibitor of the
calcineurin-NFAT pathway (16).
In developing brain, Rcan2 mRNA was expressed
widely, increased with age, and colocalized with the ex-
pression of calcineurin in some regions. The temporal in-
crease in Rcan2 expression during brain maturation was
blunted in hypothyroid animals (18, 19). In particular,
Rcan2–3 mRNA expression was reduced in cerebral cor-
tex in hypothyroid mice, but levels in other brain regions
were not affected by thyroid status (19). Thus, Rcan2-
modulated calcineurin activity was suggested to influence
brain development leading to the hypothesis that reduced
Rcan2 expression could account for some of the adverse
consequences of hypothyroidism during brain develop-
ment (18, 19). In additional studies, the expression of
Rcan2–1 in the heart was increased after T3 administra-
tion (19, 20), but no effects were observed in other tissues
in response tohyperthyroidism(19).Taken together, these
findings indicate that T3 regulation of Rcan2–3 and
Rcan2–1 expression in vivo is isoform and tissue specific
and suggest that Rcan2maymediate some of the effects of
thyroid hormones in T3-target tissues (18–20).
Although Rcan2 functions as an endogenous inhibitor
of the calcineurin-NFAT signaling, it is not known
whether Rcan2 is also expressed in bone. To investigate
and determine the physiological importance of Rcan2 in
bone, we generated Rcan2/ knockout mice and char-
acterized their skeletal phenotype. We further hypothe-
sized thatRcan2may be a T3-responsive target gene in the
skeleton because both T3 and the calcineurin-NFAT path-
way regulate bone mass via actions in osteoblasts and os-
teoclasts (8, 12, 21). Thus,we also investigated expression
of Rcan2 in skeletal cells and in T3 receptor mutant and
thyroid manipulated mice. The effect of T3 on Rcan2 ex-
pression and downstream signaling was investigated in
primary osteoblast cultures.
Materials and Methods
Rcan2/ and Rcan2/ mice
Rcan2 knockout mice (Rcan2/) were generated by replac-
ing exon 4, common to both Rcan2–1 (ZAKI-4) and Rcan2–3
(ZAKI-4), with a LacZ/Neo cassette, and Northern blot anal-
ysis confirmed the absence of both transcripts inRcan2/mice
(22) (Fig. 1). Heterozygous Rcan2/ mice were backcrossed
and established in a C57B/6J genetic background in the animal
facility at theResearch Institute ofEnvironmentalMedicine (Na-
goya University, Nagoya, Japan) using protocols approved by
the institutional review board. The adult mice were given two ip
FIG. 1. Mouse Rcan2 gene. Genomic organization of the mouse
Rcan2 gene showing the alternative splicing events that lead to
expression of Rcan2–1 and Rcan2–3 isoforms. The locations of RT-PCR
primers are also shown.
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injections of calcein (15 mg/kg in saline with 2% NaHCO3) 7
and 4 d before the animals were killed at postnatal day (P) 112.
Manipulation of thyroid status in wild-type (WT)
mice
Hypothyroid mice were fed a low iodine diet containing
0.15% (wt/vol) of the antithyroid drug propylthiouracil from
P70 for 6 wk. Hyperthyroid mice were treated with TSH-sup-
pressive doses of T4 (1.2 g/ml in drinking water) from P70 for
6 wk. Manipulation of thyroid status was performed under li-
cense in compliancewith theAnimals (Scientific Procedures) Act
1986, and the studies were approved by the local Imperial Col-
lege London Biological Services Unit ethical review process.
Skeletal preparations and histology
P1mice and limbs from older animals were stained with aliz-
arin red and alcian blue (23, 24) and photographed using a Leica
MZ75 binocular microscope, KL1500 light source, DFC320
digital camera, and IM50Digital ImageManager (all fromLeica
AG, Heerbrugg, Switzerland). The angle of the clavicle, skull
dimensions, and open fontanelle and suture areas were calcu-
latedusing ImageJ1.43n (http://rsb.info.nih.gov/ij/). Limbswere
fixed in 10% neutral buffered formalin and decalcified in 10%
EDTA. Sections were stained with van Gieson and alcian blue.
Proliferative and hypertrophic zones in growth plate sections
were identifiedasdescribed (25–27).Measurements fromat least
four separate positions across the width of tibial growth plates
were obtained using a Leica DM LB2 microscope and Leica
DFC320 digital camera to calculate mean values for the heights
of the reserve, proliferative, and hypertrophic zones and total
growth plate. Results from two levels of sectioning were com-
pared with ensure consistency.
Faxitron digital x-ray microradiography
Digital x-ray imageswere recorded at 10mresolution using
a FaxitronMX20 variable kilovolt point projection x-ray source
and digital image system operating at 26 kV and5 magnifica-
tion (Qados; Cross Technologies PLC, Berkshire, UK). Images
were calibrated with a digital micrometer and bone lengths and
caudal vertebra heights determined using ImageJ [National In-
stitutes of Health (NIH)]. Cortical bone thickness and diameter
were determined at 10 locations in the middiaphysis. Relative
FIG. 2. Skeletal development and growth in Rcan2/ mice. A, Upper and lower limbs show detail of the upper limb paws and rib cages from P1
WT, Rcan2/, and Rcan2/ mice stained with alcian blue (cartilage) and alizarin red (bone). B, Proximal tibia growth plates from P28 WT,
Rcan2/, and Rcan2/ mice stained with alcian blue and van Gieson (osteoid) (50 and 200). E, Epiphysis; GP, growth plate; RZ, reserve zone;
PZ, proliferative zone; HZ, hypertrophic zone. Bars, 200 m. C, Growth plate and chondrocyte zone heights in P28 mice (n  3 per genotype) and
linear growth analysis from birth to P112 (n  3–4 per genotype). No statistical differences, ANOVA, Rcan2/, and Rcan2/ vs. WT. Humerus
middiaphysis cortical bone thickness at P28 (n  4 per genotype), ANOVA, Rcan2/, and Rcan2/ vs. WT. *, P  0.05, Tukey’s post hoc test. D,
Skulls and clavicles from P1 WT, Rcan2/, and Rcan2/ mice. Bars, 1000 m. E, Area of skull fontanelles, clavicle angle, and length in P1 WT,
Rcan2/, and Rcan2/ mice (n  4 per genotype), ANOVA, Rcan2/, and Rcan2/ vs. WT. *, P  0.05, Tukey’s post hoc test.
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mineral content was determined by comparison with steel, alu-
minum wire, and polyester fiber standards. The 2368  2340
16-bit DICOM images were converted to 8-bit Tiff images using
ImageJ (NIH), and the histogram stretched
between polyester (gray level 0) and steel
(gray level 255) standards. Gradations of
mineralizationdensitywere represented in 16
equal intervals by a pseudocolor scheme (28).
Biomechanical testing
Boneswere storedand tested in70%eth-
anol. Destructive three-point bend tests
were performed using an Instron 5543 load
frame and 100 N load cell (Instron Ltd.,
High Wycombe, Buckinghamshire, UK).
Bones were positioned horizontally and
centered on custom supports, and the load
was applied vertically to the midshaft with
a constant rate of displacement of 0.03mm/
sec until fracture. A span of 5.6 mm was
used. Biomechanical variables were derived
from the load displacement curves as de-
scribed previously (28–31).
Destructive compression tests were also
performedon caudal vertebrae6 and7 (Ca6
and Ca7) using a 500 N load cell. Vertebral
height and diameter was determined using
ImageJ (NIH). Parallel surfaces were cut
through adjacent intervertebral discs, and
vertebrae were fixed to the center of the
lower compression anvil with cyanoacry-
late glue. The load was applied vertically
with a constant rate of displacement of 0.03
mm/sec until failurewith load displacement
data acquired at 100 Hz. Load-displace-
ment curves were plotted and yield load,
displacement at yield, maximum load, dis-
placement at maximum load, and stiffness
were determined. Work energy was calcu-
lated from the area under the load displace-
ment curve atmaximum load. Elastic stored
energyatmaximumloadwasdeterminedby
calculating the area of a right-angled trian-
gle with the vertex at the point ofmaximum
load and a hypotenuse with a slope equal to
that of the linear phase of the load-displace-
ment curve. Energy dissipated at maximum
load was calculated by subtracting the elas-





Long bones were fixed in 70% ethanol
and opened longitudinally along anatomi-
cal curvatures as described (28). Samples
were coated with carbon and imaged using
backscattered electrons at 20 kV beam po-
tential in a Zeiss DSM962 digital scanning
electron microscope equipped with an an-
nular solid state BSE detector (KE Electronics, Toft, Cam-
bridgeshire, UK). The images provide detailed views of bone
FIG. 3. Faxitron and biomechanical analysis in Rcan2/ mice during growth. A, Images of
humerus and vertebrae from P28 WT, Rcan2/, and Rcan2/ mice. Gray-scale images were
pseudocolored according to a 16-color palette in which low mineral content is black and high
mineral content is white. Bars, 1000 m. No statistical differences in humerus length or
caudal vertebra height, ANOVA, Rcan2/, and Rcan2/ vs. WT were seen. B, Relative and
cumulative frequency histograms of bone mineralization densities (n  3 per genotype).
Kolmogorov-Smirnov test, Rcan2/, or Rcan2/ vs. WT. **, P  0.01; ***, P  0.001. C,
Representative load-displacement curves from destructive three-point bend testing of P28
WT, Rcan2/, and Rcan2/ humeri showing yield load, maximum load, fracture load, and
the gradient of the linear elastic phase (stiffness). Load-displacement curves from compression
testing of P28 WT, Rcan2/, and Rcan2/ caudal vertebrae show yield load, maximum
load, and stiffness. D, Graphs showing yield, maximum, and fracture loads and stiffness of
WT, Rcan2/, and Rcan2/ humeri. No statistical differences, ANOVA (n  4 per
genotype), were seen. Graphs showing yield and maximum loads and stiffness of WT,
Rcan2/, and Rcan2/ vertebrae. No statistical differences, ANOVA (n  4 per genotype),
were seen.
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surfaces andmicroarchitecture fromwhich surface activity states
(forming, resting, resorbing, resorbed) can be investigated (32,
33). The fraction of the trabecular and endosteal surfaces that
displayed osteoclastic bone resorption was quantified using Im-
ageJ (NIH).
Quantitative BSE-SEM (qBSE-SEM)
Bone micromineralization density was determined at cubic
micron resolution by qBSE-SEM. Block faces were cut through
polymethylmethacrylate-embedded specimens and analyzed in
the SEM operated at 20 kV and 0.5 nA at a working distance of
17 mm (11 mm sample to detector). Gradations of micromin-
eralization density were represented in eight equal intervals by a
pseudocolor scheme as described (28, 34–36).
Microcomputed tomography(CT) analysis
Humeri were analyzed by micro-CT (Skyscan 1172a; Kon-
tich, Belgium) at 50 kV and 200 A using a 0.5-mm aluminum
filter and a detection pixel size of 4.3m2. Scanned images were
reconstructed using Skyscan NRecon software (28). One cubic
millimeter of area, 0.2 mm from the growth plate, was selected
as the region of interest. Trabecular bone volume as proportion
of tissue volume (percentage), trabecular thickness (millimeters),
trabecular number (millimeters1), and structure model index
were analyzed in the region of interest using the Skyscan CT
analysis software. Cortical bone volume (cubic millimeters) was
also determined in the region of interest.
Osteoclastic bone resorption
Osteoclast numberswere determined in samples fixed in10%
neutral buffered formalin and decalcified in 10% EDTA (pH
7.4). Sections were stained for tartrate-resistant acid phospha-
tase (TRAP) using a Sigma TRAP kit (386A-1KT; Sigma, Poole,
Dorset, UK) and photographed at 200 magnification using a
Leica DM LB2 microscope and DFC320 digital camera and a
montage of nine overlapping fields constructed for each bone,
representing an area of approximately 1 mm2. Osteoclast num-
bers (Oc.N) and surface (Oc.S) were determined in trabecular
bone and normalized to total bone surface (BS). Measurements
commenced 0.2 mm below the growth plate (25, 26).
Osteoblastic bone formation
Midline longitudinal and midcoronal block faces were cut
through methacrylate embedded specimens and examined using
a Leica SP2 reflection confocal microscope with 488 nm excita-
tion and10/1.0 and40/1.25 objectives to determine the frac-
tion of bone surface undergoing active bone formation as de-
scribed (28, 37). Mineral apposition rate (MAR) was calculated
by determining calcein separation at between 10 and 20 loca-
tions per specimen using ImageJ (NIH). Montages of trabecular
bone were generated and the BS and mineralizing surface (MS)
measured using ImageJ. Bone formation rate (BFR) was calcu-
lated from the product of MS and MAR. Measurements com-
menced 0.2 mm below the growth plate.
Semiquantitative RT-PCR
cDNA was synthesized from total RNA (2.5 g), and 1 l
cDNA was used for PCR amplification of Rcan2–1, Rcan2–3,
and Gapdh (38). The nucleotide (nt) positions indicate the lo-
cations of PCR primers within the GenBank reference sequence:
Rcan2–1 forward primer, Rcan2–1 F (nt 294–313), reverse
primer Rcan2–1R (nt 530–511) (GenBank NM_207649);
Rcan2–3 forward primer, Rcan2–3 F (nt 205–224), reverse
primer, Rcan2–3R (nt 423–404) (NM_030598); Gapdh for-
wardprimer,GapdhF (nt658–677), reverseprimer,GapdhR(nt
881–863) (NM_008084) (Fig. 1). PCRwere performed with an
initial denaturation step at 94 C for 2 min, cycles of 30 sec at 94
C, 30 sec at an annealing temperature of 55 C, and 30 sec at 72
C, followed by a termination step at 72 C for 3 min. Semiquan-
titative RT-PCR was optimized as described (39) and cDNA
amplified using the optimized number of PCR cycles for each
gene (25 cycles forGapdh; 28 cycles forRcan2–1 andRcan2–3).
Osteoblast cultures
Calvaria were removed from 2-d-old mice and osteoblasts
isolated by sequential collagenase digestion. Osteoblasts were
cultured in 75-cm2 flasks in modified Eagle’s medium supple-
mented with 10% fetal calf serum, L-glutamine, penicillin, and
streptomycin for 72 h. Cells were replated in six-well plates
(250,000 cells/well) and maintained for 48 h before culture in
serum-free medium overnight. Cells were treated with vehicle or
T3 (100 nM) for 6 h before RNA extraction with Trizol or iso-
lation of nuclear and cytoplasmic protein fractions using anNE-
PER kit (Thermo Scientific, Waltham, MA).














WT P28 Humerus 4.3  0.6 5.1  0.7 3.4  0.5 26  4 43  4 90  2
Rcan2/ P28 Humerus 3.6  0.2 4.7  0.3 3.6  0.4 28  3 58  5 89  3
Rcan2/ P28 Humerus 3.4  0.3 4.1  0.5 3.2  0.2 22  6 51  11 88  2
WT P28 Ca6Ca7 13.9  2.2 17.2  2.2 51  6.2 35  2
Rcan2/ P28 Ca6Ca7 10.5  0.3 15.4  0.8 54  5.4 52  3
Rcan2/ P28 Ca6Ca7 9.8  1.4 13.9  1.8 56  11.5 52  10
WT P112 Humerus 8.2  0.1 13.2  1.9 11.6  1.5 61  2 33  5 46  11
Rcan2/ P112 Humerus 8.3  0.5 10.9  1.5 12.3  0.6 54  7 29  10 35  8
WT P112 Ca6Ca7 88  9 97  8 321  20 17  2
Rcan2/ P112 Ca6Ca7 77  6 86  6 329  12 18  1
P28: WT, Rcan2/, and Rcan2/ mice (n  3 per genotype); P112: WT and Rcan2/ mice (n  3 per genotype).
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Real-time RT-PCR
Total RNA was extracted from calvarial osteoblasts and
whole bones, and 1 g was reverse transcribed (QunatiTect re-
verse transcriptase kit; QIAGEN,Hilden, Germany). cDNAwas
amplified usingRcan2–1 andRcan2–3 primers described above
and -actin and 18s rRNA primers as follows: -actin forward
primer, -ActinF (nt 1035–1058), reverse primer, -ActinR (nt
1234–1209) (NM_007393); 18s rRNA forward primer, 18sF
(nt 1443–1461), reverse primer, 18sR (nt 1549–1530)
(NM_003278). RT-PCR was performed using a 7900HT Fast
real-time machine (Applied Biosystems, Foster City, CA) and
analyzed with SDS2.3 software (Applied Biosystems). PCRs
were performed with an initial denaturation step at 95 C for 10
min followed by 40 cycles of 95 C for 15sec, 30 sec at an an-
nealing temperature of 60 C, and 30 sec at 72 C, followed by a
dissociation stage to allow melt curve analysis.
Immunoprecipitation
Nuclear and cytoplasmic protein fractionswere isolated from
primary calvarial osteoblasts using a NE-PER kit (Thermo Sci-
entific). 20 g of each fraction was pre-cleared using protein
G-Sepharose beads (GE Healthcare, Hatfield, Hertfordshire,
UK) for 1 h. Cleared lysates were incubated overnight with 5 g
of anti-NFATc1 monoclonal antibody (Santa Cruz Biotechnol-
ogy, SantaCruz,CA)before the additionofprotein-G-Sepharose
beads for 1 h and collection of immunoprecipitates by centrifu-
gation. Samples were washed four times in PBS and eluted in
protein sample buffer. SDS-PAGE and Western blotting were
thenperformedusing anti-NFATc1monoclonal antibody (Santa
Cruz Biotechnology) or an antiphosphoserine antibody (Abcam,
Cambridge UK).
Statistics
Normally distributed data were analyzed by ANOVA fol-
lowed by Tukey’s multiple comparison post hoc test. P 0.05
was considered significant. Frequency distributions of bone mi-
cromineralization densities obtained by Faxitron and qBSEwere
comparedusing theKolmogorov-Smirnov test, inwhichP values
for theD statistic in 1024 pixel data sets wereD greater than
6.01,P0.05;D greater than7.20,P0.01, andD greater
than 8.62 P  0.001.
Results
Bone development in Rcan2/ mice
To determine whether deletion of Rcan2 affects bone
formation, endochondral and intramembranous ossifica-
tion was analyzed in neonatal P1 mice, and linear growth
was characterized between P1 and P112 (Fig. 2, A–E).
There were no differences in endochondral bone forma-
tion or linear growth between WT and mutant mice (Fig.
2, A–C). Consistent with these findings, histological anal-
ysis of the growth plate revealed no differences between
WT and Rcan2 mutant mice at P28 (Fig. 2, B and C). By
contrast, intramembranous ossificationwas delayed in P1
Rcan2/ mice, in which wider skull sutures and fonta-
FIG. 4. Bone microarchitecture and micromineralization in adult
Rcan2/ mice. A and B, Low-power BSE-SEM views of proximal tibia
and high-power views of distal femur from P112 WT, Rcan2/, and
Rcan2/ mice (n  3 per genotype). Bars, 200 m. C, qBSE-SEM
images of trabecular bone from proximal humerus of P112 WT,
Rcan2/, and Rcan2/ mice (n  2–4 per genotype). Gray-scale
images were pseudocolored according to an eight-color palette in
which the low mineralization density is blue and the high density is
gray. Bar, 200 m. D, Relative and cumulative frequency histograms of
trabecular bone micromineralization densities. *, P  0.05, Rcan2/
or Rcan2/ vs. WT, Kolmogorov-Smirnov test, WT (n  4), Rcan2/
(n  2), and Rcan2/ (n  4). E, qBSE-SEM images of cortical bone
from the midshaft of the humerus in WT, Rcan2/, or Rcan2/ mice.
Bar, 200 m. F, Frequency histograms of cortical bone
micromineralization densities. ***, P  0.001, Rcan2/ or Rcan2/
vs. WT, Kolmogorov-Smirnov test, WT (n  4), Rcan2/ (n  2), and
Rcan2/ (n  4).
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nelleswere present comparedwithWTmice andheterozy-
gotes, although claviclemorphologywasnormal (Fig. 2,D
and E). Cortical bone thickness was also reduced by 17%
in Rcan2/ mice in the middiaphysis of the humerus at
P28 (Fig. 2C), although this difference in cortical thickness
was not maintained at P112 (data not shown). Thus, dur-
ing skeletal development Rcan2-deficient mice display
normal endochondral ossification in the growth plate but
impaired intramembranous ossification and cortical bone
formation.
Bone mineralization and strength in juvenile
Rcan2/ mice
To determine whether deletion of Rcan2 affects bone
mineralization, bone mineral content in P28mice was an-
alyzed by Faxitron digital x-ray microradiography. Rela-
tive and cumulative frequency histograms revealed re-
duced bone mineral content in Rcan2/ mice and
reduced vertebral bone mineral content in bothRcan2/
and Rcan2/ mice (Fig. 3, A and B). To determine
whether reduced bone mineral content and cortical bone
thickness in juvenile Rcan2/mice was accompanied by
impaired bone strength, destructive three-point bend test-
ing was performed on humeri and compression testing on
caudal vertebrae from P28mice. Although biomechanical
analysis demonstrated a trend to suggest that bone
strength is impaired in Rcan2/ mice, the data did not
reach statistical significance (Fig. 3,CandD, andTable 1).
Bone microarchitecture in adult Rcan2/ mice
To investigate the structure of adult bone in Rcan2/
mice, bone microarchitecture was analyzed. Low-power
BSE-SEM views of proximal tibia revealed no differences
in cortical or trabecular bone between mutant and WT
mice at P112 (Fig. 4A). In higher-power views, the thick-
ness and connectivity of individual trabeculae was similar
among Rcan2/ and Rcan2/ and WT mice (Fig. 4B).
Accordingly, trabecular and cortical bone parameters de-
termined by micro-CT (Table 2), and cortical thickness
determined by Faxitron (data not shown), did not differ
betweenmutant andWTmice. Thus, adultRcan2mutant
mice have normal bone microarchitecture.
Bone mineralization and strength in adult Rcan2/
 mice
Detailed studies of bone mineralization were per-
formed using qBSE-SEM (Fig. 4, C–F). Frequency histo-
grams of micromineralization densities from trabecular
(Fig. 4D) and cortical bone (Fig. 4F) demonstrated in-
creased mineralization in Rcan2/ and Rcan2/ mice.
Thus, in contrast to the reduced bone mineral content
identified in juveniles, adult Rcan2 mutant mice display
increased bonemineralization. To determine whether this
increased bone mineralization was accompanied by al-
tered bone strength three-point bend and compression
testing was performed. Despite the observed changes in
mineralization, biomechanical parameters did not differ
between Rcan2/ and WT mice (Table 1).
Bone resorption and bone formation in Rcan2/
mice
To investigate whether changes in osteoclastic bone re-
sorption also occur in Rcan2 mutant mice, histomor-
phometry and BSE-SEM analyses were performed. Sec-
tions were stained for TRAP to determine the Oc.N and
quantify Oc.S in relation to the total trabecular BS (Fig. 5,
A andB), but nodifferences in these parameterswere iden-
tified between mutant and WT mice. The areas of oste-
oclastic bone resorption on trabecular and endosteal bone
surfaces were quantified in higher resolution BSE-SEM
images (Fig. 5,CandD), andnodifferenceswere identified
in the resorption surface relative to total BS between mu-
tant and WT mice.
To investigate osteoblast function and bone formation
parameters, mineralizing surfaces, MAR, and BFR were
quantified in bones from the calcein-labeled mice (Fig. 5,
E and F).Mineralizing surfaces were reduced by 54% and
MARby 29% inRcan2-deficient mice, and consequently,
bone formation rate was reduced by 67% in Rcan2/
mice. Thus, Rcan2-deficient mice exhibit an isolated de-
fect in osteoblast function but have normal osteoclast
function.
Rcan2 expression in bone
Expression of Rcan2 in the skeleton and its regulation
by thyroid hormones were investigated in primary bone
TABLE 2. Micro-CT analysis
BV/TV (%) Tb.Th (mm) Tb.N (mm1) SMI Cortical BV (mm3)
WT P112 Humerus 8.1%  0.7 0.038  0.001 2.1  0.18 1.91  0.07 0.59  0.02
Rcan2/ P112 Humerus 8.8%  2.7 0.038  0.001 2.3  0.71 1.94  0.28 0.53  0.05
WT and Rcan2/ mice (n  3 per genotype). BV/TV, Trabecular bone volume as proportion of tissue volume; Tb.Th, trabecular thickness; Tb.N,
trabecular number; SMI, structure model index; Cortical BV, Cortical bone volume.
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cell cultures from WT mice and in
bones obtained from TR knockout and
thyroid-manipulated mice. In primary
osteoclast cultures, bone marrow
monocytes and osteoclast precursors
expressed Rcan2–1 but not Rcan2–3,
whereas mature osteoclasts expressed
only Rcan2–3. By contrast, primary
osteoblasts expressed both isoforms
(Fig. 6).
Mice lacking TR (TR0/0) have im-
paired T3 signaling in bone because
they lack expression of TR, the pre-
dominant functional TR isoform in the
skeleton (26, 40). By contrast, mice
lacking TR (TR/) have increased
thyroid hormone signaling in bone due
to activation of the normal TR iso-
form by elevated circulating thyroid
hormones (25, 26). The level of
Rcan2–1 expression was similar in ju-
venile and adult TR0/0, TR/, and
WT mice, whereas expression of
Rcan2–3 was reduced by 50% in juve-
nile TR0/0 mice (Fig. 7). Consistent
with these findings, skeletal Rcan2–3
mRNA expression was increased by
more than 2-fold in thyrotoxic WT
mice compared with hypothyroid ani-
mals (Fig. 8A).
In vitro studies in primary
osteoblasts
In primary cultures of WT calvarial
osteoblasts, T3 treatment did not affect
the levels of Rcan2–1 or Rcan2–3
mRNA expression (Fig. 8B). Further-
more, T3 treatment did not alter levels
ofNFATc1 protein expression or phos-
phorylation and did not affect its rela-
tive distribution between nuclear and
cytoplasmic compartments (Fig. 8C).
Discussion
These studies demonstrate that, despite
normal endochondral ossification and
linear growth, juvenile Rcan2/ mice
display delayed intramembranous ossi-
fication, impaired cortical bone forma-
tion, and reducedbonemineral accrual.
FIG. 5. Bone turnover in Rcan2/ mice. A, TRAP-stained sections of tibia trabecular bone
from P112 WT, Rcan2/, and Rcan2/ mice. Black arrows indicate TRAP-stained
osteoclasts. Bar, 200 m. B, Quantitative analysis of Oc.S and the Oc.N relative to BS. No
statistical differences, ANOVA, WT (n  4), Rcan2/ (n  2), and Rcan2/ (n  4), were
seen. C, Endosteal bone surfaces from P112 WT, Rcan2/, and Rcan2/ mice imaged by
BSE-SEM. White arrows indicate roughened osteoclast resorption surfaces. Bar, 200 m. D,
Quantitative analysis of trabecular and endosteal osteoclast resorption surfaces (percentage of
total bone surface). No statistical differences, ANOVA, WT (n  4), Rcan2/ (n  2) and
Rcan2/ (n  4), were seen. E, Calcein labeling of trabecular bone from WT, Rcan2/, and
Rcan2/ mice. Bar, 10 m. F, Trabecular bone MS, MAR, and BFR determined by dual-
calcein labeling. ANOVA, Rcan2/ (n  2) and Rcan2/ (n  4) vs. WT (n  4), *, P  0.05
and **, P  0.01, Tukey’s post hoc test.
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Adult Rcan2/mice exhibit normal bone microarchitec-
ture but increased mineralization. Heterozygous
Rcan2/micehavean intermediatephenotype consistent
with a gene dosage effect. The skeletal abnormalities in
Rcan2/micewere accompaniedbynormalbone resorp-
tion but reduced bone formation, indicating an isolated
defect in osteoblast function. The resulting reduction in
mineral apposition rate leads to an extended bone forma-
tion phase and prolongation of the bone remodeling cycle.
This protracted phase of osteoblastic bone formation is
accompanied by a longer period of secondary mineraliza-
tion (41, 42), which results in the observed increase in
bone mineralization in adult Rcan2/ mice.
Thyroid hormones have major effects on skeletal de-
velopment and adult bone maintenance (43, 44). Hypo-
thyroidism delays bone formation and linear growth,
whereas thyrotoxicosis accelerates skeletal development
and is an important risk factor for osteoporosis. In previ-
ous studies we characterized mice with mutation or dele-
tion of TR and TR in several genetic backgrounds (21,
23–27). Juvenile TRmutants exhibit delayed endochon-
dral ossification and impaired growth, whereas juvenile
TR mutants have advanced ossification. By contrast,
adult TR mutants have increased bone mass resulting
from disrupted T3 action in bone, whereas adult TRmu-
tants are osteoporotic due to increased T3 signaling in the
skeleton as a consequence of elevated circulating thyroid
hormone concentrations (23, 40). Taken together, these
studies indicate TR mediates T3 action in bone (21).
In studies to investigate the role of TR in skeletal de-
velopment, we characterized a series of TRmutant mice
(23, 25, 26). Mice lacking TR (TR0/0) had delayed en-
dochondral ossification but normal intramembranous os-
sification and normal adult bone mineralization. By con-
trast, mice harboring a dominant-negative mutation of
TR (TR1PV/ and TR1R384C/) had delayed endo-
chondral and intramembranous ossification accompanied
by increased adult bone mineralization (23, 25, 26). In
further studies we showed that expression of the type 2
deiodinase enzyme (DIO2), which generates T3 in thyroid
hormone-responsive target cells, is restricted to differen-
tiated osteoblasts in the skeleton (45). Accordingly,Dio2
knockout mice (Dio2/) exhibited a discrete defect of
osteoblast function, resulting in increased adult bonemin-
FIG. 6. Rcan2 mRNA expression in primary osteoblasts and
osteoclasts. A, Rcan2–1, Rcan2–3, and Gapdh mRNA expression in
primary osteoblasts (M; size marker). Ob, Osteoblasts; Br, brain; Ht,
heart; and C, no template control. B, Rcan2–1 and Rcan2–3 expression
in primary osteoclasts (Mo; bone marrow monocytes). Oc D1,
Osteoclast precursors (d 1 of culture); and Oc D5, mature osteoclasts
(d 5 of culture).
FIG. 7. Rcan2 mRNA expression in bone from TR knockout mice. A,
Rcan2–1 and Rcan2–3 mRNA expression in juvenile WT, TR0/0, and
TR/ bone at age P21. B, Rcan2–1 and Rcan2–3 mRNA expression in
adult WT, TR0/0, and TR/ bone at age P70. C, Graphs showing
Rcan2–1 and Rcan2–3 mRNA expression, normalized to Gapdh, in
bone from juvenile TR0/0 and TR/ mice compared with WT.
ANOVA, Rcan2// and Rcan2/ vs. WT. *, P  0.05, Tukey’s post
hoc test, n  4 per genotype. D, Graphs showing Rcan2–1 and Rcan2–
3 mRNA expression, normalized to Gapdh, in bone from adult TR0/0
and TR/ mice compared with WT. No significant difference,
ANOVA, n  4 per genotype, was seen.
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eralization (28). Thus, the findings of delayed intramem-
branous ossification and increased adult bonemineraliza-
tion identified in Rcan2/ mice are similar to those in
micewithosteoblast defects due todominant negativemu-
tations of TR or deletion of Dio2.
Cell-specific gene targeting has demonstrated that the
calcineurin-NFAT pathway is a negative regulator of os-
teoblast differentiation (12). Thus, deletion of the endog-
enous calcineurin inhibitor RCAN2would be expected to
inhibit osteoblast activity further by removal of tonal in-
hibition of calcineurin activity in osteoblasts. The findings
of delayed intramembranous ossification, impaired corti-
cal bone formation, and reduced bone mineral accrual
during development, together with increased bone min-
eralization in adultRcan2/, mice are all consistent with
this hypothesis. Together with the previous similar find-
ings in TR and Dio2 mutant mice (23, 25, 26, 28), the
skeletal phenotype ofRcan2/mice suggests that Rcan2
may lie downstream of T3 signaling in osteoblasts.
We therefore investigated thyroid hormone regulation
of Rcan2 expression in skeletal cells in vivo and in vitro.
Both Rcan2–1 and Rcan2–3 mRNA were expressed in
bone in vivo and, consistent with previous studies in fi-
broblasts (16), only theRcan2–3 isoformwas regulatedby
thyroid status or deletion of TR. In vitro studies dem-
onstrated that expression of Rcan2–1 and Rcan2–3 was
bone cell lineage specific anddependent on the stage of cell
differentiation.Osteoblasts expressed bothRcan2mRNA
isoforms and immature osteoclast precursor cells ex-
pressed only Rcan2–1, whereas mature differentiated os-
teoclasts expressed only Rcan2–3. The absence of an os-
teoclast phenotype in Rcan2/mice suggests the actions
ofRcan2 are dispensable in the osteoclast lineage, and this
may reflect redundancy in regulationof calcineurin/NFAT
signaling. Expression of both Rcan2 transcripts in osteo-
blasts suggests that Rcan2 may mediate some of the ac-
tions of T3 in osteoblasts.
To address this, primary osteoblasts were treated with
T3. Even though skeletal Rcan2–3 expression was in-
creased in thyrotoxic animals, T3 treatment did not affect
Rcan2–3 or Rcan2–1 expression in primary osteoblasts.
Furthermore, immunoprecipitation studies to investigate
expression of the calcineurin target gene NFATc1 and its
phosphorylation in cytoplasmic and nuclear compart-
ments also revealed no response to T3. These in vitro stud-
ies suggest that, even though skeletal expression ofRcan2
is regulated by thyroid status in vivo, the phenotype iden-
tified in Rcan2/ mice is unlikely to result directly from
disruption of T3 signaling in osteoblasts.
Nevertheless, the current studies establish that Rcan2
regulates osteoblast activity during growth and mainte-
nance of bone mineralization in adults.
FIG. 8. Rcan2 mRNA expression in whole bone and primary
osteoblasts from WT mice and expression and phosphorylation of
NFATc1 in WT osteoblasts treated with T3. A, Rcan2–1 and Rcan2–3
mRNA expression in whole bone from hypothyroid and thyrotoxic
P112 WT mice. Unpaired Student’s t test, hypothyroid vs. thyrotoxic. *,
P  0.05, n  3 per group. B, Rcan2–1 and Rcan2–3 mRNA expression
in primary calvarial osteoblasts obtained from WT mice. No significant
difference, unpaired Student’s t test, hypothyroid vs. thyrotoxic, n  3
per group, was seen. C, Immunoprecipitation and Western blot
analysis of total and phosphorylated NFATc1 in nuclear and
cytoplasmic protein fractions from cultured primary calvarial
osteoblasts treated with vehicle or T3 (100 nM). No significant
difference, unpaired Student’s t test, vehicle vs. T3, n  3 per group,
was seen.
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